DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Digestive System Fistula - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Digestive System Fistula - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the diseas...
January 2022
60 pages
Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and...
January 2022
60 pages
Diphtheria - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Diphtheria - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
DNA gyrase inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 hours DelveInsight’s, “DNA gyrase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 13+ pipeli...
January 2022
60 pages
DNA topoisomerase I inhibitors - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 3-4 Business Days DelveInsight’s, “DNA topoisomerase I inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ compan...
January 2022
80 pages
DNA topoisomerase inhibitors - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “DNA topoisomerase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+...
January 2022
80 pages
Doose Syndrome - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Doose Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histori...
January 2022
60 pages
Dopamine D1 receptor antagonists - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “Dopamine D1 Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and...
January 2022
60 pages
Dopamine receptor antagonists - Pipeline Insight, 2022
US$ 2,000.00
This report can be delivered to the clients within 2-3 working days DelveInsight’s, “Dopamine receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companie...
January 2022
60 pages
Down Syndrome - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Down Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historic...
January 2022
60 pages
Dravet Syndrome (DS) - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Dravet Syndrome (DS) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, h...
January 2022
60 pages
Dravet Syndrome - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Dravet Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
Drug Hypersensitivity - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Drug Hypersensitivity - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
Drug Resistant Epilepsy - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Drug Resistant Epilepsy - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease...
January 2022
60 pages
Ductal Carcinoma in Situ - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Ductal Carcinoma in Situ - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the diseas...
January 2022
60 pages
Dup15q Syndrome - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Dup15q Syndrome - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, histor...
January 2022
60 pages
Dupuytren Contracture - Epidemiology Forecast - 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Dupuytren Contracture - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease,...
January 2022
60 pages
DUX4 protein inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 hours DelveInsight’s, “DUX4 protein inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeli...
January 2022
60 pages
Dyschromia - Epidemiology Forecast to 2032
US$ 3,950.00
This report can be delivered to the clients within 5-7 Business Days DelveInsight's 'Dyschromia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical...
January 2022
60 pages
